MEDIA ALERT: European Lung Cancer Conference Preview


Media Contact: ELCC Press Office

MEDIA ALERT: European Lung Cancer Conference Preview

GENEVA – ESMO and IASLC are pleased to invite journalists to a media brief taking place at the beginning of the European Lung Cancer Conference (ELCC) in the Palexpo Centre in Geneva, on Friday 5 May 2017, from 12:00 to 12:45 CEST.

The Scientific Co-Chairs of ELCC 2017, Professors Martin Reck (ESMO) and Andrew Nicholson (IASLC), will be present to answer media questions, as well as Professor Solange Peters from the ELCC Scientific Committee.

Some of the news that will be released about ELCC 2017 includes:

  • Men need more frequent lung cancer screening than women
  • White blood cell counts can predict whether lung cancer patients will benefit from immunotherapy
  • Osimertinib improves symptoms in advanced lung cancer patients
  • Annual flu jab may pose greater risk for cancer patients on checkpoint inhibitors
  • Some lung cancer patients benefit from immunotherapy even after disease progression
  • Patients with NSCLC respond best to salvage chemotherapy when pre-treated with PD-1/PD-L1 inhibitors

Three late breaking studies will be announced at ELCC 2017:

  • LBA1: Establishment of a diagnostic algorithm for ROS1 testing in Canada
  • LBA2_PR: Use of G-CSF and prophylactic antibiotics with concurrent chemo-radiotherapy in limited-stage small cell lung cancer: results from the phase III CONVERT trial
  • LBA3: Correlation between clinical outcomes of patients treated within the TAILOR trial and Next-Generation Sequencing (NGS) results: analysis of genes associated to KRAS mutations

Martin Reck, Germany, said: “Some of the most exciting developments in lung cancer will be discussed at ELCC. One of the foremost today is immunotherapy. I look forward to the abstract sessions, where important new data about the activity of anti-PDL1 antibodies in first-line treatment and in patients with squamous cell NSCLC will be presented. I also look forward to the updated educational program, which will provide a comprehensive overview of the development of the emergent field of immunotherapy in thoracic tumors.

Andrew Nicholson, UK, said: “It is difficult to choose one area when there is so much progress in diagnosis, prognosis and advances in targeted therapy and immunotherapy, but I am excited about presentation on the setting up of ROS1 testing in Canada, because it presents issues on how testing for rare abnormalities can be nationally implemented.”

Lung cancer killed approximately 1,590,000 persons in 2012 and is currently the leading cause of cancer death worldwide. Tobacco use is a major risk factor for lung cancer and is responsible for approximately 22% of cancer-related deaths globally. Lung cancer is the leading cause of cancer deaths in males and the second leading cause in females globally. In 2012, lung cancer killed an estimated 1,098,700 men and 491,200 women worldwide, corresponding to 24% and 14% of all cancer deaths in males and females, respectively. In developed countries, it is now the leading cause of cancer death in females, surpassing breast cancer. 

The European Lung Cancer Conference is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.

View the online program here.

Media registration

Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.

Media representatives are required to observe and abide by the ELCC Media Policy

To register for the event, please fill out the complimentary Media Registration Form.

April 20, 2017